OSCR
Oscar Health, Inc.
OSCR has a slight edge over PDEX overall, supported by stronger fundamentals.
PDEX
Pro-Dex, Inc.
PDEX has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PDEX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
PDEX's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over PDEX in the historical PE scenario, which offers more potential upside but is not a forecast.
PDEX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $52.76 | -22% |
| Fair | 18x | $65.13 | -3.4% |
| Current | 19x | $67.42 | — |
| Forward | 21x | $67.42 | — |
| Expensive | 24x | $88.76 | +32% |
Historical ranges are pointers, not guarantees.
PDEX's PE is in its fair range at 19x. On analysts' estimates for next year's earnings, today's price would be 21x, in its expensive range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over PDEX on the outlook, with more favorable valuation expectations.
PDEX Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for PDEX, with profitability improving.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
PDEX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.18 | -13% |
| Q3 2026 | $3.64 | +9.6% |
| Q2 2026 | $4.12 | +54% |
| Q1 2026 | $3.59 | +29% |
| Q4 2025 | $3.37 | +69% |
| Q3 2025 | $3.32 | +118% |
| Q2 2025 | $2.67 | +345% |
| Q1 2025 | $2.78 | +415% |
| Q4 2024 | $1.99 | +180% |
PDEX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PDEX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PDEX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.6M | +11% |
| Q2 2026 | $20.4M | +17% |
| Q1 2026 | $19.9M | +15% |
| Q4 2025 | $18.7M | +11% |
| Q3 2025 | $18.5M | +24% |
| Q2 2025 | $17.5M | +16% |
| Q1 2025 | $17.4M | +22% |
| Q4 2024 | $16.8M | +33% |
PDEX's revenue has grown year over year for 13 quarters in a row: $21M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +0.3 points |
| Q2 2026 | 17% | +9.6 points |
| Q1 2026 | 16% | -5.4 points |
| Q4 2025 | 17% | +1.4 points |
| Q3 2025 | 17% | -3.4 points |
| Q2 2025 | 7.7% | -8 points |
| Q1 2025 | 21% | +5.4 points |
| Q4 2024 | 16% | +9.9 points |
PDEX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PDEX on cash flow, with more consistent year-over-year improvement.
PDEX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.1M | +178% |
| Q2 2026 | -$476K | -$303K |
| Q1 2026 | $1.5M | +165% |
| Q4 2025 | $3.5M | +$8.2M |
| Q3 2025 | $2.2M | +52% |
| Q2 2025 | -$173K | -117% |
| Q1 2025 | $574K | -86% |
| Q4 2024 | -$4.7M | -6194% |
PDEX's free cash flow has turned positive again: $11M over the past year, against −$2M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PDEX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -1.6K shares |
| 1 year | -0.7% | -23.4K shares |
| 3 years | -8.8% | -322K shares |
| 5 years | -17% | -660K shares |
PDEX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $600,000 |
| Q2 2026 | $600,000 |
| Q1 2026 | $601,000 |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $1.2M |
| Q3 2024 | $2.3M |
| Q2 2024 | $1.7M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over PDEX on leverage, with a lower net debt burden relative to earnings.
PDEX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 1.0x | Very low |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
PDEX's net debt is less than a year of its operating earnings (EBITDA), down from 1.1 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PDEX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.7 | Neutral |
| Stochastic | 34.8 | Neutral |
PDEX's weekly RSI is 56 (neutral) and its Stochastic is 35 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over PDEX on valuation relative to its sector.
PDEX PE vs Healthcare Sector
| Metric | PDEX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 55 | 29 | 26 pts above |
PDEX is trading at 19x earnings, a 28% discount to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
PDEX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.4 | 6.3% above |
| 20 week MA | $63.6 | 6% above |
| 50 week MA | $54.9 | 23% above |
| 100 week MA | $48.6 | 39% above |
| 200 week MA | $34.6 | 95% above |
PDEX is in an uptrend: it's above all five of its weekly moving averages, and 95% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PDEX on returns for 2026, with the stronger performance.
PDEX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.6 | $39.5 | +137% |
| 2021 | $39.5 | $23.6 | -40% |
| 2022 | $23.6 | $16.4 | -30% |
| 2023 | $16.4 | $17.5 | +6.8% |
| 2024 | $17.5 | $49.3 | +181% |
| 2025 | $49.3 | $39.5 | -20% |
| 2026 YTD | $39.5 | $67.4 | +71% |
PDEX's yearly returns have swung widely, from +181% in 2024 to −40% in 2021. It's up 71% so far in 2026.